Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

The aptamer BT200 blocks interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1

Alain Chion, Ciara Byrne, Ferdows Atiq, Dearbhla Doherty, Sonia Aguila, Judicael Fazavana, Patricia Lopes, Ellie Karampini, Aamir Amin, Roger J. S. Preston, Ross I. Baker, Thomas A. J. McKinnon, Shuhao Zhu, James C. Gilbert, Jonas Emsley, Bernd Jilma, James S. O’Donnell

Blood (2024) 144 (13): 1445–1456.

https://doi.org/10.1182/blood.2024024055

Published: 2024

Includes: Supplemental data

Journal Articles

The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A

Cihan Ay, Katarina D. Kovacevic, Daniel Kraemmer, Christian Schoergenhofer, Georg Gelbenegger, Christa Firbas, Peter Quehenberger, Petra Jilma-Stohlawetz, James C. Gilbert, Shuhao Zhu, Martin Beliveau, Franz Koenig, Alfonso Iorio, Bernd Jilma, Ulla Derhaschnig, Ingrid Pabinger

Blood (2023) 141 (10): 1147–1158.

https://doi.org/10.1182/blood.2022016571

Published: 2023

Includes: Supplemental data

Journal Articles

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial

Ulrich Jäger, Shirley D’Sa, Christian Schörgenhofer, Johann Bartko, Ulla Derhaschnig, Christian Sillaber, Petra Jilma-Stohlawetz, Michael Fillitz, Thomas Schenk, Gary Patou, Sandip Panicker, Graham C. Parry, James C. Gilbert, Bernd Jilma

Blood (2019) 133 (9): 893–901.

https://doi.org/10.1182/blood-2018-06-856930

Published: 2019

Includes: Supplemental data

Journal Articles

Long Term Efficacy, Safety and PK/PD Profile of the Anti-C1s Antibody (BIVV009) in Primary Cold Agglutinin Disease Patients

Ulrich Jaeger, MD, Shirley D'Sa, MD FRCP, FRCPath, Christian Schoergenhofer, MD, Johann Bartko, MD, Christian Sillaber, MD, Petra Jilma-Stohlawetz, MD, Michael Fillitz, MD, Thomas Schenk, MD, Gary Patou, MD, Sandip Panicker, PhD, Graham C Parry, PhD, James C Gilbert, MD, Bernd Jilma, MD

Blood (2017) 130 (Supplement 1): 703.

https://doi.org/10.1182/blood.V130.Suppl_1.703.703

Published: 2017

Journal Articles

Chronic Inhibition of Complement C1s By TNT009 Produces Sustained, Complete Remission in Patients with Severe, Transfusion-Dependent Cold Agglutinin Disease (CAD)

Bernd Jilma, MD, James C Gilbert, MD, Sandip Panicker, PhD, Graham C Parry, PhD, Michael Fillitz, MD, Schenk Thomas, Christian Sillaber, MD, Johann Bartko, MD, Ulrich Jaeger, MD

Blood (2016) 128 (22): 2435.

https://doi.org/10.1182/blood.V128.22.2435.2435

Published: 2016

Journal Articles

TNT009 Prevents Erythrocyte C3 Fragment Opsonization and Rescues Reticulocytes from Destruction in Patients with Cold Agglutinin Disease

Sandip Panicker, PhD, Christa Drucker, Sami Hussain, Graham C Parry, PhD, James C Gilbert, MD, Bernd Jilma, MD, Ulrich Jaeger, MD

Blood (2016) 128 (22): 94.

https://doi.org/10.1182/blood.V128.22.94.94

Published: 2016

Journal Articles

Therapeutic Rationale and Clinical Development of TNT009, an Upstream Classical Pathway Inhibitor, for Cold Agglutinin Disease

Ulrich Jaeger, MD, Eileen L Rose, Andrew Singh, Sebastian H A Feickert, Simon Panzer, Bernd Jilma, MD, James C. Gilbert, MD, Sandip Panicker, PhD

Blood (2015) 126 (23): 3560.

https://doi.org/10.1182/blood.V126.23.3560.3560

Published: 2015

Journal Articles

The Anti Von Willebrand Factor Aptamer ARC1779 Prevents the Desmopressin-Induced Thrombocytopenia in VWD Type 2B.

Petra Paulinska, MD, Bernd Jilma, MD, Christa Firbas, MD, Robert G Schaub, PhD, James C. Gilbert, MD, Paul Knoebl, MD

Blood (2008) 112 (11): 3374.

https://doi.org/10.1182/blood.V112.11.3374.3374

Published: 2008

Journal Articles

Proof of Concept for the Anti Von Willebrand Factor Aptamer in Patients with Relapsing Thrombotic Thrombocytopenic Purpura (TTP).

Bernd Ji lma, MD, Petra Jilma, MD, Petra Paulinska, MD, James C. Gilbert, MD, Renta Hutabarat, PhD, Trish Wagner, Paul Knoebl, MD

Blood (2008) 112 (11): 2290.

https://doi.org/10.1182/blood.V112.11.2290.2290

Published: 2008

Journal Articles

Anti Von Willebrand Factor Aptamer ARC 1779 for Refractory Thrombotic Thrombocytopenic Purpura.

Chri sta Firbas, MD, Bernd Jilma, MD, Patricia G Wagner, Renta Hutabarat, Robert G Schaub, PhD, James C. Gilbert, MD, Paul Knoebl, MD

Blood (2008) 112 (11): 2298.

https://doi.org/10.1182/blood.V112.11.2298.2298

Published: 2008

Journal Articles

The Aptamer ARC1779 Potently and Specifically Inhibits the Excessive von Willebrand Factor (vWF) Activity and vWF-Mediated Ex Vivo Platelet Function of Patients with Thrombotic Thrombocytopenic Purpura (TTP).

Bernd Jilma, MD, Florian B. Mayr, MD, Paul Knoebl, MD, Alexander O. Spiel, MD, Patricia G. Merlino, Robert Schaub, PhD, James C. Gilbert, MD

Blood (2007) 110 (11): 279.

https://doi.org/10.1182/blood.V110.11.279.279

Published: 2007

NARROW

The aptamer BT200 blocks interaction of K1405-K1408 in the VWF-A1 domain with macrophage LRP1

The von Willebrand factor–binding aptamer rondaptivon pegol as a treatment for severe and nonsevere hemophilia A

Inhibition of complement C1s improves severe hemolytic anemia in cold agglutinin disease: a first-in-human trial

Long Term Efficacy, Safety and PK/PD Profile of the Anti-C1s Antibody (BIVV009) in Primary Cold Agglutinin Disease Patients

Chronic Inhibition of Complement C1s By TNT009 Produces Sustained, Complete Remission in Patients with Severe, Transfusion-Dependent Cold Agglutinin Disease (CAD)

TNT009 Prevents Erythrocyte C3 Fragment Opsonization and Rescues Reticulocytes from Destruction in Patients with Cold Agglutinin Disease

Therapeutic Rationale and Clinical Development of TNT009, an Upstream Classical Pathway Inhibitor, for Cold Agglutinin Disease

The Anti Von Willebrand Factor Aptamer ARC1779 Prevents the Desmopressin-Induced Thrombocytopenia in VWD Type 2B.

Proof of Concept for the Anti Von Willebrand Factor Aptamer in Patients with Relapsing Thrombotic Thrombocytopenic Purpura (TTP).

Anti Von Willebrand Factor Aptamer ARC 1779 for Refractory Thrombotic Thrombocytopenic Purpura.

The Aptamer ARC1779 Potently and Specifically Inhibits the Excessive von Willebrand Factor (vWF) Activity and vWF-Mediated Ex Vivo Platelet Function of Patients with Thrombotic Thrombocytopenic Purpura (TTP).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only